FdaApplication
BLA 125813
Identifiers
- fda_app_no: BLA125813
Properties
| Property | Value |
|---|---|
| applicant_name | Autolus, Inc. |
| application_type | BLA |
| approval_date | 2024-11-08 |
Revenue by product
AUCATZYL
| Period | Revenue |
|---|---|
| Q2 2026 | $45.7M |
| Q1 2026 | $26.2M† |
| Q3 2025 | $21.1M |
| Q1 2025 | $9.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AUCATZYL | — | 410 10^6CAR+ T CELLS TOTAL; DELIVERED AS A SPLIT DOSE IN 3-5 BAGS ON DAY 1 & 10 | Suspension |
1 product